<DOC>
	<DOCNO>NCT02607943</DOCNO>
	<brief_summary>Hyperglycemia common acute ischemic stroke . However , optimal strategy control hyperglycemia acute ischemic stroke establish . The object multicenter randomize control study determine efficacy safety early initiation subcutaneous once-daily insulin glargine , comparison regular insulin , base protocolized slide scale regimen achieve proper sugar control acute stroke patient hyperglycemia admit intensive care unit .</brief_summary>
	<brief_title>Insulin Glargine Versus Regular Insulin Based Regimens Glycemic Control After Acute Stroke</brief_title>
	<detailed_description>Study Rationale : Hyperglycemia common acute ischemic stroke . It show persistent in-hospital hyperglycemia first 24 hour ( h ) stroke associated bad outcome normoglycemia . However , optimal strategy control hyperglycemia acute ischemic stroke establish . Aims : The object multicenter randomize control study determine efficacy safety early initiation subcutaneous once-daily insulin glargine , comparison regular insulin , base protocolized slide scale regimen achieve proper sugar control acute stroke patient hyperglycemia admit intensive care unit ( ICU ) . Design : This 3-year , randomize , multicenter trial . Approximate 120 hyperglycemic acute stroke patient receive either ( ) subcutaneous long act basal insulin ( insulin glargine ) add short act regular insulin correct hyperglycemic event ( b ) short act regular insulin pre-meal add NPH bed time start eating , 72 h , start within 24 h stroke symptom onset . The inclusion criterion patient admit stroke ICU within 24 hour acute stroke onset repeat random blood glucose &gt; 200 mg/dL 2 hour interval . The exclusion criterion include patient age &lt; 20 year , pregnancy , shock , severe infection , end stage renal disease require dialysis , type I DM current steroid usage . Capillary blood glucose measure every 4-hours adjust next insulin dose . Glucometric parameter also analyze continuous blood glucose monitoring system . 10 ml blood amount urine 24 hour urine collection collect every day measurement variety blood inflammatory marker urine catecholamine level . Study outcomes : The primary endpoint percentage time range 80-180 mg/dL sugar monitoring period . The secondary endpoint include : ( 1 ) good functional outcome 3 month post stroke ( modify Rankin Scale &lt; 2 ) , ( 2 ) stroke evolution , ( 3 ) 24 hour blood glucose variability via continuous glucose monitoring , ( 4 ) blood urine biomarkers . In summary , trial provide important novel information prefer management acute ischemic stroke patient hyperglycemia . It determine potential benefit risk application long act basal insulin early stage acute stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients admit stroke ICU within 24 hour acute stroke onset repeat random blood glucose &gt; 200 mg/dL 2 hour interval Patients age &lt; 20 year , pregnancy , shock , severe infection , end stage renal disease require dialysis , type I DM current steroid usage .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>acute stroke</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>regular insulin</keyword>
	<keyword>long-acting insulin</keyword>
</DOC>